Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors
- 977 Downloads
Numerous technical and functional advances in next-generation sequencing (NGS) have led to the adoption of this technique in conventional clinical practice. Recently, large-scale genomic research and NGS technological innovation have revealed many more details of somatic and germline mutations in solid tumors. This development is allowing for the classification of tumor type sub-categories based on genetic alterations in solid tumors, and based on this information, new drugs and targeted therapies are being administered to patients. This has largely been facilitated by gene panel testing, which allows for a better understanding of the genetic basis for an individual’s response to therapy. NGS-based comprehensive gene panel testing is a clinically useful approach to investigate genomic mechanisms, including therapy-related signaling pathways, microsatellite instability, hypermutated phenotypes, and tumor mutation burden. In this review, we describe the concept of precision medicine in solid tumors using NGS-based comprehensive gene panel testing, as well as the importance of quality control of tissue sample handling in routine NGS-based genomic testing, and we discuss issues for the future adoption of this technique in Japan.
KeywordsNext-generation sequencing Precision medicine Solid tumors Genomic panel test Hypermutation Tumor mutation burden
Compliance with ethical standards
Conflict of interest
Toshifumi Wakai received remuneration from Denka Company Limited and received research funding from Denka Company Limited, Eisai Co., Ltd.; Taisho Toyama Pharmaceutical Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; Sumitomo Dainippon Pharma Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Eli Lilly Japan K.K.; and Yakult Honsha Co., Ltd. Pankaj Prasoon, Yuki Hirose, Yoshifumi Shimada, Hiroshi Ichikawa, and Masayuki Nagahashi have no conflict of interest to disclose.
- 27.Le Tourneau C, Delord JP, Goncalves A et al (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16:1324–1334CrossRefPubMedGoogle Scholar